Cd8-based pharmaceuticals

Details Cd8-based pharmaceuticals Cd8-based pharmaceuticals

C - Chemistry, Metallurgy

12

N

C12N 15/12 (2006.01) A61K 35/28 (2006.01) A61K 38/17 (2006.01) A61K 39/00 (2006.01) A61K 47/48 (2006.01) A61L 27/00 (2006.01) C07K 14/705 (2006.01) C12N 15/866 (2006.01) A61K 38/11 (2006.01)

Patent

CA 2050346

2050346 9010385 PCTABS00002 The inhibitory ligand function of the T lymphocyte-associated peptide CD8 is disclosed, enabling the development of CD8-based peptide pharmaceuticals. Specific and nonspecific immunomodulation, enhancement of cellular engraftment, and modulation of nonimmune cells are achieved by using various membrane-binding and soluble CD8 peptides and biomembranes, such as cells and liposomes, bearing CD8 peptides. Methods for producing useful CD8 peptides, including glycoinositolphospholipid-modified CD8 and CD8:ligand conjugates, via recombinant DNA techniques, are also disclosed.

Affiliated with

Also associated with

Rating

Cd8-based pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cd8-based pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cd8-based pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2018704